On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to the already existing manufacturing arrangement, SK Bioscience had obtained a license to manufacture and commercialize NVX-CoV2373, Novavax COVID-19 vaccine, for sale to the Korean government.

SK Bioscience planned additional production capacity under this new agreement. Novavax had reported positive interim efficacy results for the vaccine candidate in Phase 3 clinical trial in the UK and was conducting a Phase 3 trial in the U.S. and Mexico.